Systematic review of immunoglobulin use in paediatric neurological and neurodevelopmental disorders

Gadian, Jonathan; Kirk, E.; Holliday, Kate L.; Lim, Ming; Absoud, Michael

doi:10.1111/dmcn.13349

Cited by 25 publications

(8 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, a randomized controlled study of IVIG for PANDAS in 35 children failed to demonstrate that IVIG was more effective than placebo. 125 Gadian et al 121 reviewed the literature, which suggested that IVIG may speed recovery in SC, and recommended that IVIG be considered in severe cases of SC (grade C evidence). Testing revealed serial declines in Wechsler verbal, performance, and full-scale intellectual quotients.…”

Section: 124mentioning

confidence: 99%

Psychiatric Treatment and Management of Psychiatric Comorbidities of Movement Disorders

Walsh

Soe

Sarawgi

2018

Seminars in Pediatric Neurology

View full text Add to dashboard Cite

Pediatric movement disorders may present with psychiatric symptoms at many points during the course of the disease. For the relatively common pediatric movement disorder, Tourette syndrome, psychiatric comorbidities are well-described and treatment is well-studied. Managing these comorbidities may be more effective than improving the movements themselves. For more uncommon movement disorders, such as juvenile-onset Huntington disease, treatment of psychiatric comorbidities is not well-characterized, and best-practice recommendations are not available. For the least common movement disorders, such as childhood neurodegeneration with brain iron accumulation, psychiatric features may be nonspecific so that underlying diagnosis may be apparent only after recognition of other symptoms. However, psychiatric medication, psychotherapy, and psychosocial support for these disorders may prove helpful to many children and adolescents.

show abstract

Section: 124mentioning

confidence: 99%

Psychiatric Treatment and Management of Psychiatric Comorbidities of Movement Disorders

Walsh

Soe

Sarawgi

2018

Seminars in Pediatric Neurology

View full text Add to dashboard Cite

show abstract

“…In addition, IVIGs may be helpful in other neurological diseases, such as multiple sclerosis, autoimmune encephalitis, and resistant epilepsy. 11,17 In our study, 22 (11.8%) patients received IVIG treatments for neurological diseases, and the most common indication in this groups was GBS (n=12).…”

mentioning

confidence: 61%

The use of intravenous immunoglobulin therapy in a tertiary pediatric hospital

Güngör

Yaralı

2020

SMJ

View full text Add to dashboard Cite

Objectives: To determine demographic features of patients provided intravenous immunoglobulin (IVIG) excluding replacement therapy in the inpatient services and to evaluate indications for IVIG, and side effects related to therapy. Methods: Patients who received IVIG therapy between January 2016 and August 2018 were retrospectively identified. The demographic features, diagnosis, IVIG dose, number of days they underwent IVIG therapy, and whether or not they experienced IVIG-related side effects were recorded. Results: A total of 186 patients were included in this study, and of these, 89 (47.8%) were females. The median age of all of the patients was 48.5 months old (range 13-120 months). When the IVIG indications Original Article were examined, the hematological disease group had the highest number of patients (n=73, 39.2%). The US Food and Drug Administration (FDA) labeled use rate was 45.7%. Side effects were seen in 15 (3.81%) of the 394 IVIG infusions, 2 of which were acute kidney failure and nausea/vomiting as delayed onset side effects. The rapid onset side effects included fever (n=5), headache (n=3), rash and redness (n=2), and pain in the infusion area, hypotension, and hypertension (n=1). Conclusion: Intravenous immunoglobulin preparations are used for the treatment of many diseases due to their immunoregulatory effects. In recent years, the use of IVIGs without FDA approval has been increasing.

show abstract

“…Thus, we cannot rule out a possible influence of the POLR3A in the clinical features presented by our patient. High doses of IVIG are broadly used for the treatment of autoimmune diseases of different etiologies, including ADEM [20]. However, the use of low doses of IVIG in ADEM-ON has not been extensively documented.…”

Section: Discussionmentioning

confidence: 99%

Whole exome sequencing in a child with acute disseminated encephalomyelitis, optic neuritis, and periodic fever syndrome: a case report

Ledesma

Guerra

Burbano³

et al. 2019

J Med Case Reports

View full text Add to dashboard Cite

BackgroundAcute disseminated encephalomyelitis is generally preceded by an infection, and it is usually self-limiting and non-recurrent. However, when there are multiple attacks of acute disseminated encephalomyelitis followed by optic neuritis, it is defined as acute disseminated encephalomyelitis-optic neuritis. To the best of our knowledge, there are no previous reports of acute disseminated encephalomyelitis and optic neuritis preceded by autoinflammation, triggered by periodic fever syndrome.Case summaryWe report on a case of acute disseminated encephalomyelitis with optic neuritis and periodic fever syndrome in a 12-year-old Ecuadorian Hispanic boy with several relapses over the past 10 years, always preceded by autoinflammatory manifestations and without evidence of infectious processes. Whole exome sequencing was performed, and although the results were not conclusive, we found variants in genes associated with both autoinflammatory (NLRP12) and neurological (POLR3A) phenotypes that could be related to the disease pathogenesis having a polygenic rather than monogenic trait.ConclusionWe propose that an autoinflammatory basis should be pursued in patients diagnosed as having acute disseminated encephalomyelitis and no record of infections. Also, we show that our patient had a good response after 1 year of treatment with low doses of intravenous immunoglobulin and colchicine.

show abstract

Systematic review of immunoglobulin use in paediatric neurological and neurodevelopmental disorders

Abstract: IVIG is a useful therapy in selected neurological conditions. Well-designed, prospective, multi-centre studies with standardized outcome measures are required to compare treatments.

Cited by 25 publications

References 90 publications

Psychiatric Treatment and Management of Psychiatric Comorbidities of Movement Disorders

Psychiatric Treatment and Management of Psychiatric Comorbidities of Movement Disorders

The use of intravenous immunoglobulin therapy in a tertiary pediatric hospital

Whole exome sequencing in a child with acute disseminated encephalomyelitis, optic neuritis, and periodic fever syndrome: a case report

Contact Info

Product

Resources

About